Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

12.5%

1 terminated/withdrawn out of 8 trials

Success Rate

85.7%

-0.8% vs industry average

Late-Stage Pipeline

13%

1 trials in Phase 3/4

Results Transparency

33%

2 of 6 completed trials have results

Key Signals

1 recruiting2 with results

Enrollment Performance

Analytics

Phase 2

1(33.3%)

Phase 3

1(33.3%)

N/A

1(33.3%)

3Total

Phase 2(1)

Phase 3(1)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT04300920Phase 3Completed

Prospective Treatment Efficacy in IPF Using Genotype for Nac Selection (PRECISIONS) Trial

Role: collaborator

NCT05382572Recruiting

Pulmonary Fibrosis Foundation Community Registry

Role: lead

NCT04273867Completed

Assessing Health Related Quality of Life in Hypersensitivity Pneumonitis

Role: collaborator

NCT02758808Completed

Pulmonary Fibrosis Foundation Patient Registry

Role: lead

NCT01961362Completed

Supplemental Oxygen in Pulmonary Fibrosis

Role: collaborator

NCT01935726Completed

Pulmonary Fibrosis Contact Registry

Role: collaborator

NCT02600689Not ApplicableCompleted

Home-Based Pulmonary Rehab for Patients With Pulmonary Fibrosis

Role: collaborator

NCT00981747Phase 2Terminated

Targeting Vascular Reactivity in Idiopathic Pulmonary Fibrosis

Role: collaborator

All 8 trials loaded